FluoGuide (FLUO) Stock Overview
A clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
FLUO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
FluoGuide A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 32.80 |
| 52 Week High | SEK 47.80 |
| 52 Week Low | SEK 28.00 |
| Beta | 0 |
| 1 Month Change | 0.31% |
| 3 Month Change | -20.19% |
| 1 Year Change | -18.20% |
| 3 Year Change | -61.68% |
| 5 Year Change | -71.08% |
| Change since IPO | 492.06% |
Recent News & Updates
FLUO: Positive Cancer Surgery Trial Data Will Support Future Upside
Analysts have trimmed their price target on FluoGuide to SEK59.12 from SEK73.85, citing updated assumptions around revenue growth, profit margins and a slightly higher discount rate, along with a modestly higher future P/E multiple. What’s in the News for FluoGuide FluoGuide reported positive results from Part 1 of its FG001-CT-005 Phase 2 trial in oral head and neck cancer, achieving the primary endpoint of identifying an optimal FG001 dose of 0.30 mg/kg.FLUO: Strong Brain Tumor Surgery Data Will Support Future Upside
Analysts have revised their price target for FluoGuide to SEK73.85 from SEK123.50, citing updated assumptions on revenue potential, profitability, and a higher future P/E multiple within their valuation work. What’s in the News for FluoGuide FluoGuide presented interim data for its FG001 compound in an investigator-initiated clinical study involving surgery for meningioma and presumed low grade glioma (pLGG).Recent updates
FLUO: Positive Cancer Surgery Trial Data Will Support Future Upside
Analysts have trimmed their price target on FluoGuide to SEK59.12 from SEK73.85, citing updated assumptions around revenue growth, profit margins and a slightly higher discount rate, along with a modestly higher future P/E multiple. What’s in the News for FluoGuide FluoGuide reported positive results from Part 1 of its FG001-CT-005 Phase 2 trial in oral head and neck cancer, achieving the primary endpoint of identifying an optimal FG001 dose of 0.30 mg/kg.FLUO: Strong Brain Tumor Surgery Data Will Support Future Upside
Analysts have revised their price target for FluoGuide to SEK73.85 from SEK123.50, citing updated assumptions on revenue potential, profitability, and a higher future P/E multiple within their valuation work. What’s in the News for FluoGuide FluoGuide presented interim data for its FG001 compound in an investigator-initiated clinical study involving surgery for meningioma and presumed low grade glioma (pLGG).Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
Catalysts About FluoGuide FluoGuide develops imaging agents that light up cancer during surgery to help surgeons remove tumors more precisely. What are the underlying business or industry changes driving this perspective?Health Check: How Prudently Does FluoGuide (STO:FLUO) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. Indeed, FluoGuide ( STO:FLUO ) stock...Shareholder Returns
| FLUO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.5% | 3.4% | -1.3% |
| 1Y | -18.2% | 26.7% | 10.4% |
Return vs Industry: FLUO underperformed the Swedish Biotechs industry which returned 26.7% over the past year.
Return vs Market: FLUO underperformed the Swedish Market which returned 10.4% over the past year.
Price Volatility
| FLUO volatility | |
|---|---|
| FLUO Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.1% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: FLUO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: FLUO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 7 | Morten Albrechtsen | fluoguide.com |
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
FluoGuide A/S Fundamentals Summary
| FLUO fundamental statistics | |
|---|---|
| Market cap | SEK 536.26m |
| Earnings (TTM) | -SEK 62.49m |
| Revenue (TTM) | SEK 350.85k |
Is FLUO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUO income statement (TTM) | |
|---|---|
| Revenue | DKK 238.00k |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 238.00k |
| Other Expenses | DKK 42.63m |
| Earnings | -DKK 42.39m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 25, 2026
| Earnings per share (EPS) | -2.59 |
| Gross Margin | 100.00% |
| Net Profit Margin | -17,810.92% |
| Debt/Equity Ratio | 63.3% |
How did FLUO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 02:56 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FluoGuide A/S is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oliver Røst Benneballe | DNB Carnegie Commissioned Research |
| Fredrik Thor | Redeye |
| Christian Binder | Redeye |